Skin Microbiome and Psoriasis: What the Research Shows

What happens to the skin microbiome in psoriasis?

Psoriatic skin harbors significantly fewer bacterial species than healthy skin, with dramatic shifts in which microbes dominate. Lesional psoriatic plaques show enrichment of Staphylococcus aureus, various Streptococcus species, and Corynebacterium species, while beneficial commensals like Cutibacterium acnes and Staphylococcus epidermidis become less abundant. This pattern represents a loss of the normal balance that keeps skin functioning as an effective immune barrier.

The fungal community also changes in psoriasis, though findings vary across studies. Research has detected alterations in Malassezia species composition on psoriatic skin, with some studies reporting increased Malassezia restricta and Malassezia globosa on plaques. These yeasts may contribute to inflammation through metabolites and cell wall components that activate pattern-recognition receptors on immune cells.

The degree of dysbiosis often correlates with disease severity, suggesting that microbial shifts track with the inflammatory state. Non-lesional psoriatic skin—areas that appear normal but carry genetic susceptibility—shows intermediate microbial profiles between healthy and lesional skin.

Does dysbiosis cause psoriasis or result from it?

The directionality question remains one of the most debated aspects of psoriasis microbiome research. Current evidence suggests that microbial changes are primarily a consequence of the inflammatory environment, altered skin pH, and rapid keratinocyte turnover that characterize psoriatic plaques. The thickened, scaly surface and altered antimicrobial peptide production create a new ecological niche that favors different microbes.

However, once established, dysbiotic communities likely amplify inflammation through a feedback loop. S. aureus produces superantigens and other virulence factors that directly activate T cells and stimulate keratinocyte proliferation—key processes in psoriasis pathogenesis. Bacterial peptidoglycans and lipoteichoic acid can trigger Toll-like receptors, promoting production of inflammatory cytokines like TNF-α and IL-17.

Studies in mouse models suggest that certain microbial patterns can influence the severity of psoriasis-like inflammation, though direct causation in human disease remains unproven. The most accurate current framework views psoriasis as a genetically driven inflammatory disease that creates microbial dysbiosis, which then perpetuates and potentially worsens inflammation.

Which specific microbes are linked to psoriasis severity?

Staphylococcus aureus colonization is one of the most consistent findings in psoriasis microbiome research. This opportunistic pathogen appears on lesional skin in 20-65% of psoriasis patients depending on the study, compared to much lower rates on healthy skin. Its presence correlates with more severe PASI scores (Psoriasis Area and Severity Index) and worse clinical outcomes.

Streptococcus pyogenes deserves special attention because streptococcal throat infections are well-established triggers for guttate psoriasis, an acute form characterized by small, drop-like lesions. Streptococcal M proteins act as superantigens that activate T cells bearing specific receptor subtypes, directly linking a specific microbe to disease flares. Even in chronic plaque psoriasis, increased Streptococcus species on skin may contribute to exacerbations.

The role of Malassezia species is more complex and may be particularly relevant in scalp psoriasis. These lipophilic yeasts produce inflammatory lipid mediators and can trigger innate immune responses through C-type lectin receptors. Some evidence suggests that antifungal treatments improve scalp psoriasis in subsets of patients, though this remains an area needing more rigorous research.

Can treating the microbiome improve psoriasis symptoms?

Standard psoriasis treatments—topical corticosteroids, vitamin D analogs, biologics—all affect the skin microbiome secondarily by reducing inflammation. Studies of patients on biologic therapy show that bacterial diversity gradually increases and S. aureus colonization decreases as skin lesions clear. This suggests that successful treatment of the underlying immune dysfunction allows the microbiome to normalize, though it typically doesn't fully return to healthy patterns.

Direct microbiome-targeting approaches remain experimental in psoriasis. Small studies of topical probiotics containing S. epidermidis or its antimicrobial peptides have shown modest benefits, possibly by competitively excluding S. aureus and modulating local immune responses. Phototherapy, particularly narrowband UVB, also appears to shift microbial communities alongside its direct effects on keratinocytes and T cells.

Antiseptic bleach baths, which reduce S. aureus burden in atopic dermatitis, have not been systematically studied in psoriasis. Given the different immune pathways involved, interventions that work in one inflammatory skin disease cannot be assumed effective in another without proper testing.

The bottom line

Psoriatic skin shows clear microbial dysbiosis with reduced diversity and increased colonization by Staphylococcus aureus and Streptococcus species, which likely perpetuates inflammation even if not the original cause. As psoriasis treatments improve skin inflammation, microbial communities partially normalize, suggesting that managing the immune dysfunction remains the primary therapeutic target while microbiome changes serve as a useful biomarker of disease activity.